After 2 months of treatment, all laboratory tests and clinical evaluations were repeated as per the initial visit. During the treatment, all patients were visited and interviewed about possible side effects, and to determine the degree of compliance.
After baseline assessment all patients took 50,000 units of vitamin D 3 weekly, for 2 month. Written consent was obtained from all participants. Inclusion criteria were absence of hepatic, renal and bone diseases, malignancy, any history of the use of drugs such as insulin, anticonvulsants, calcium, vitamin D and an HbA 1c <8% for the last three months. We also assessed liver function by measuring serum concentration of AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) to rule out liver disease and major non alcoholic fatty disease of the liver as exclusion criteria that might affect vitamin D metabolism. HOMA − IR : FPG mmol / L × Insulin μ Iu / ml 22.5 HOMA-IR (Hemostatic model assessment-Insulin resistance) was calculated based on following formula : Serum 25(OH)D was measured by radioimmunoassay(RIA) (kits manufactured by Biosource Europe SA, Belgium). All results were presented as Mean±SD, or medians of non-normally distributed.Ģ4% of the participants were Vitamin D deficient, insulin, Ca(Calcium), P(Phosphorous) and ALP(Alkaline Phosphatase). Resultsġ00 participants including 70 women (70%) and 30 men (30%) took part in the study. The results were analyzed by descriptive tests, and a comparison between variables were made using paired T-tests or Wilcoxon tests, as appropriate.
Patients received 50,000 unit of vitamin D 3 orally per week for eight weeks, Statistical analysis was made using SPSS17. All measurements were performed at the beginning and the end of the study.
Serum insulin and, 25(OH)D concentration, and HOMA-IR was calculated. Participants were assessed for clinical and biochemistry. Through a before-after study, 100 patients with T2DM, 30–70 years old, were recruited from an Arak diabetes clinic as consecutive attenders. This study evaluates the effects of vitamin D supplementation on insulin resistance in T2DM. Different studies provide evidence that vitamin D may play a functional role in glucose tolerance through its effects on insulin secretion and insulin sensitivity. Over the past decade, numerous non-skeletal diseases have been reported to be associated with vitamin D deficiency including type2 diabetes mellitus (T2DM).
0 kommentar(er)
